
Guggenheim has decided to maintain its Buy rating of Rubius Therapeutics (NASDAQ:RUBY) and lower its price target from $25.00 to $5.00.
Shares of Rubius Therapeutics are trading down 24.14% over the last 24 hours, at $2.42 per share.

Guggenheim has decided to maintain its Buy rating of Rubius Therapeutics (NASDAQ:RUBY) and lower its price target from $25.00 to $5.00.
Shares of Rubius Therapeutics are trading down 24.14% over the last 24 hours, at $2.42 per share.